About Immunicon
Immunicon is a company based in Bryn Athyn (United States) founded in 1983 by Paul Liberti was acquired by CellSearch in June 2008. Immunicon has raised $75.35 million across 5 funding rounds from investors including NIH, LHC Group and Canaan. Immunicon operates in a competitive market with competitors including NanoCellect Biomedical, ThinkCyte, Singulex, Cell Microsystems and Silicon Biosystems, among others.
- Headquarter Bryn Athyn, United States
- Founders Paul Liberti
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$75.35 M (USD)
in 5 rounds
-
Latest Funding Round
$940 K (USD), Grant
Jun 01, 2015
-
Investors
NIH
& 11 more
-
Employee Count
Not available
-
Acquired by
CellSearch
(Jun 11, 2008)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Immunicon
Immunicon has successfully raised a total of $75.35M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $940 thousand completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Immunicon
Immunicon has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, LHC Group and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech-based companies are invested in by Wheatley Partners.
|
Locked | Locked | Locked | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked | |
|
Early-stage tech startups are funded by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for Immunicon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immunicon
Investment portfolio details for Immunicon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Immunicon
Detailed financials for Immunicon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immunicon Comparisons
Peer comparison for Immunicon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immunicon
Immunicon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NanoCellect Biomedical, ThinkCyte, Singulex, Cell Microsystems and Silicon Biosystems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Develops flow cytometry and cell sorting technology
|
|
| Locked | Locked | Locked |
Cell analysis and sorting technologies are developed with AI integration.
|
|
| Locked | Locked | Locked |
Single-molecule counting technology is developed for cardiovascular biomarker detection.
|
|
| Locked | Locked | Locked |
Developer of a technology to isolate and recover single cells for molecular analysis
|
|
| Locked | Locked | Locked |
Lab-on-a-chip technologies for miniaturized cell-biology testing are developed.
|
Detailed competitors of Immunicon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunicon
Complete news archive for Immunicon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immunicon
Immunicon was founded in 1983 and raised its 1st funding round 17 years after it was founded.
Immunicon is headquartered in Bryn Athyn, United States. It is registered at Bryn Athyn, Pennsylvania, United States.
Immunicon is a funded company, having raised a total of $75.35M across 5 funding rounds to date.
Founded in 1983 in Bryn Athyn, United States, Immunicon focused on biotechnology for cancer disease management. Platform technologies were developed to identify and characterize rare cells in blood, such as circulating tumor cells. Diagnostic and research products were commercialized, while analytical services were provided to pharmaceutical and biotechnology firms for therapeutic development. The company was acquired by Veridex in August 2008.
Immunicon's top competitors include NanoCellect Biomedical, ThinkCyte and Silicon Biosystems.
Immunicon has 12 investors. Key investors include NIH, LHC Group, Canaan, Burrill and Company, and CellSearch.